Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma
- 155 Downloads
M30 and M65 are circulating fragments of cytokeratin 18 released during apoptotic cell death and regarded as markers of cell death in patients with various tumor types. Our aim was to investigate the clinical and prognostic significance of the serum M30 and M65 concentrations in patients with advanced nasopharyngeal carcinoma. Thirty-two patients with nasopharyngeal cancer and 32 control subjects were investigated. Serum samples were obtained on first admission before any treatment was initiated. Serum M30 and M65 concentrations were measured by quantitative enzyme-linked immunosorbent assay. Median serum M30 (181.5 vs. 45.5 U/L, p < 0.001) and M65 (384.2 vs. 179.1 U/L, p < 0.001) concentrations were significantly higher in patients with advanced nasopharyngeal carcinomas than in controls. receiver operating characteristic (ROC) analysis showed that a cutoff for M30 of 225 U/L had a sensitivity of 62.5 % and a specificity of 73.9 % (area under the curve (AUC) = 0.592, 95 % confidence interval (CI) 35.3–83.2, p = 0.44), while a cutoff for M65 of 423.4 U/L had a sensitivity of 75.1 % and a specificity of 65.6 % (AUC = 0.562, 95 % CI 36.0–76.5, p = 0.60). However, serum M30 and M65 were not important prognostic factors for progression-free survival. There were no statistically significant correlations between serum M30 and M65 concentrations and clinicodemographical variables. Serum M30 and M65 concentrations were found to have a diagnostic value in nasopharyngeal cancer. However, neither M30 nor M65 serum levels played a prognostic role in the outcome in nasopharyngeal cancer patients.
KeywordsBiomarker Cytokeratin 18 Diagnostic value Nasopharyngeal carcinoma Serum M30 level Serum M65 level
This work has no funding source.
Conflicts of interest
- 3.Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, Zhang Y, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer. 2010;10:558. doi: 10.1186/1471-2407-10-558.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Lv X, Xiang YQ, Cao SM, Qian CN, Li NW, Guo L, et al. Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: more distant metastases and shorter overall survival after treatment. Head Neck. 2011;33(6):780–5. doi: 10.1002/hed.21541.CrossRefPubMedGoogle Scholar
- 6.Chang KP, Hao SP, Chang JH, Wu CC, Tsang NM, Lee YS, et al. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin Cancer Res. 2008;14(21):6979–87. doi: 10.1158/1078-0432.CCR-08-0090.CrossRefPubMedGoogle Scholar
- 12.Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest. 2006;24(7):669–76. doi: 10.1080/07357900600981307.CrossRefPubMedGoogle Scholar
- 15.Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R, et al. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol. 2009;35(11):1164–8. doi: 10.1016/j.ejso.2009.02.007.CrossRefPubMedGoogle Scholar
- 20.SB BD, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual 7th ed ed. New York, NY: Springer; 2010Google Scholar
- 21.Wu YX, Wang JH, Wang H, Yang XY. Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis. Zhonghua bing li xue za zhi Chin J Pathol. 2003;32(4):314–8.Google Scholar